Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro

British Journal of Pharmacology

Volumn 151, Issue 3, 2007, Pages 384-395

  Michael, H ^a   Harkonen P L ^a,b   Kangas, L ^c   Vaananen H K ^a   Hentunen, T A ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c Finland   (Finland)

Author keywords

Bone resorption; Ospemifene; Osteoclast differentiation; Osteoprotegerin; Raloxifene; Tamoxifen

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLONY STIMULATING FACTOR 1; DEXAMETHASONE; FULVESTRANT; OSPEMIFENE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RALOXIFENE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; MALE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD14; APOPTOSIS; BONE RESORPTION; CATTLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MONOCYTES; OSTEOCLASTS; OSTEOPROTEGERIN; RALOXIFENE; RANK LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249690772     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707232     Document Type: Article

References (75)

1. Alatalo SL, Halleen JM, Hentunen TA, Monkkonen J, Vaananen HK (2000). Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 46: 1751-1754.
2. Arnett TR, Lindsay R, Kilb JM, Moonga BS, Spowage M, Dempster DW (1996). Selective toxic effects of tamoxifen on osteoclasts, comparison with the effects of oestrogen. J Endocrinol 149: 503-508.
3. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC et al. (1994). Roloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 207: 19-37.
4. Bord S, Horner A, Beavan S, Compston J (2001). Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab 86: 2309-2314.
5. Braidman IP, Davenport LK, Carter DH, Selby PL, Mawer EB, Freemont AJ (1995). Preliminary in situ identification of estrogen target cells in bone. J Bone Miner Res 10: 74-80.
6. Braidman IP, Hainey L, Batra G, Selby PL, Saunders PT, Hoyland JA (2001). Localization of estrogen receptor beta protein expression in adult human bone. J Bone Miner Res 16: 214-220.
7. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C et al. (1998). Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268.
8. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G (2003). Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells, comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 177: 423-433.
9. Clarke R, van der Berg HW, Murphy RF (1990). Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17beta-estradiol. J Natl Cancer Inst 82: 1702-1705.
10. Clemons M, Danson S, Howel A (2002). Tamoxifen (Nolvadex), a review. Cancer Treat Rev 28: 165-180.
11. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ et al. (1995). The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593.
12. Compston JE (2001). Sex steroids and bone. Physiol Rev 81: 419-447.
13. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women, results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189-2197.
14. De Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F (1991). Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51: 5165-5170.
15. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al. (1997). Effect of raloxifene on bone mineral density, serum cholesterol concerntrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647.
16. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C (1996). A controlled trial of raloxifene (LY139481) HCL, impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11: 835-842.
17. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC et al. (1988). Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241: 84-86.
18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene, results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645.
19. Evans G, Bryant HU, Magee D, Sato M, Turner RT (1994). The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134: 2283-2288.
20. Evans GL, Bryant HU, Magee DE, Turner RT (1996). Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult overectomized rats with estabilished osteopenia. Endocrinology 137: 4139-4144.
21. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. (1998). Tamoxifen for prevention of breast cancer, report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Int 90: 1371-1388.
22. Fournier B, Haring S, Kaye AM, Somjen D (1996). Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J Endocrinol 150: 275-285.
23. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Ripply MK, Cole HW et al. (1995). Raloxifene is a tissue selective agonist/ antagonist that functions through the estrogen receptor. Ann NY Acad Sci 761: 355-360.
24. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S et al. (2004). Raloxifene modulated interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 89: 6097-6099.
25. Grodstein F, Stampfer MJ (1998). Estrogen for women at varying risk of coronary disease. Maturitas 30: 19-26.
26. Halbreich U (1997). Role of estrogen in postmenopausal depression. Neurology 48: 16-19.
27. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1998). Osteoprotegrin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein and cytokines. Biochem Biophys Res Commun 250: 776-781.
28. Huang WH, Lau AT, Daniels LL, Fujii H, Seydel U, Wood DJ et al. (1998). Detection of estrogen receptor-α, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNAs in putative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in situ hybridization. J Mol Endocrinol 20: 211-219.
29. Jevon M, Sabokbar A, Fujikawa Y, Hirayama T, Neale SD, Wass J et al. (2002). Gender- and age-related differences in osteoclast formation from circulating precursors. J Endocrinol 172: 673-681.
30. Kallio A, Zheng A, Heiskanen K, Harkonen P (2005). Role of mitochondria in tamoxifen-induced death of MCF-7 breast cancer cells. Apoptosis 10: 1395-1410.
31. Kanis JA (1996). Estrogens, the menopause, and osteoporosis. Bone 19: 185-190.
32. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O (2004). Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 18: 152-158.
33. Komi K, Lankinen KS, Degegorio M, Heikkinen J, Saarakoski S, Tuppurainen M et al. (2006). Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 24: 314-318.
34. Lehenkari P, Parikka V, Rautila TJ, Weckstrom M, Dahllund J, Harkonen PL et al. (2003). The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J Bone Miner Res 18: 473-481.
35. Liao EY, Luo XH, Su X (2002). Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest 25: 785-790.
36. Lobo RA (1995). Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 173: 982-990.
37. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ (1994). Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 28: 2585-2588.
38. Mahonen A, Maenpaa PH (1994). Steroid hormone modulation of vitamin D receptor levels in human MG-63 osteosarcoma cells. Biochem Biophys Res Commun 205: 1179-1186.
39. Mano H, Yuasa T, Kameda T, Miyazawa K, Nakamaru Y, Shiokawa M et al. (1996). Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun 223: 637-642.
40. Marshburn PB, Carr BR (1992). Hormone replacement therapy, protection against the consequences of menopause. Postgrad Med J 92: 145-159.
41. Michael H, Harkonen PL, Vaananen HK, Hentunen TA (2005a). Estrogen and testosterone inhibit osteoclastogenesis through different cellular pathways. J Bone Miner Res 20: 2224-2232.
42. Michael H, Nyman JK, Vaaraniemi J, Vaananen HK, Hentunen TA (2005b). Characterization of circulating human osteoclast progenitors, development of in vitro resorption assay. Calcif Tissue Int 76: 222-230.
43. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T et al. (1998). Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247: 610-615.
44. Narayana Murthy PS, Sengupta S, Sharma S, Singh MM(2006). Effects of ormeloxifene on ovarioectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF-beta-3 expression. J Steroid Biochem Mol Biol 100: 117-128.
45. Oreffo RO, Kusec V, Vidi AS, Flangan AM, Grano M, Zambonin-Zallone A et al. (1999). Expression of estrogen receptor-α in cells of the osteoclastic lineage. Histochem Cell Biol 111: 125-133.
46. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC (1991). Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88: 6613-6617.
47. Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simonici E et al. (2004). Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15: 1749-1759.
48. Parikka V, Lehenkari PP, Harkonen PK, Vaananen HK (1998). The effect of two selective estrogens raloxifene and FC1271a on osteoclast survival and resorption in vitro. Bone 23 (Suppl): S552.
49. Pensler JM, Langman CB, Radosevich JA, Maminta ML, Mangkornkanok M, Higbee R et al. (1990). Sex steroid hormone receptors in normal and dysplastic bone disorders in children. J Bone Miner Res 5: 493-498.
50. Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E et al. (1996). Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59: 401-410.
51. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S (1996). Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84.
52. Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z et al. (2000). Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 141: 809-820.
53. Qu Q, Harkonen PL, Vaananen HK (1999). Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 73: 500-507.
54. Ramalho AC, Couttet P, Baudoin C, Morieux C, Graulet AM, De Vernejoul MC et al. (2002). Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur Cytokine Netw 13: 39-45.
55. Riggs BL (1991). Overview of osteoporosis. West J Med 154: 63-77.
56. Sato M, Rippy MK, Bryant HU (1996). Raloxifene, tamoxifene, nofoxidine or estrogen effects on reproductive and non-reproductive tissue in overiectomized rats. FASEB 10: 905-912.
57. Selander K, Lehenkari P, Vaananen HK (1994). The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 55: 368-375.
58. Shevde NK, Bendixen AC, Dienger KM, Pike JW (2000). Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-jun expression. Proc Natl Acad Sci USA 97: 7829-7834.
59. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. (1997). Osteoprotegerin a novel secreted protein involved in regulation of bone density. Cell 89: 309-319.
60. Stewart PJ, Stern PH (1986). Effects of the antiestrogens tamoxifen tamoxifen and clomiphene on bone resorption in vitro. Endrocrinology 118: 125-131.
61. Su X, Liao EY, Peng J, Wu XP (2003). The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells. Zhonghua Nei Ke Za Zhi 42: 800-803.
62. Sutherland MK, Hui DU, Rao LG, Wylie JN, Murray TM (1996). Immunohistochemical localization of the estrogen receptor in human osteoblastic SaOS-2 cells, association of receptor levels with alkaline phosphatase activity. Bone 18: 361-369.
63. Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G et al. (2002). The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30: 368-376.
64. Tiitinen A, Nikander E, Hietanen P, Metsa-Heikkila M, Ylikorkela O (2004). Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. Maturitas 48: 321-327.
65. Tonetti DA, Jordan VC (1996). Targeted anti-estrogens to treat and prevent diseases in women. Mol Med Today 5: 218-223.
66. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP et al. (1992). High-dose oral tamoxifen, a potential multidrug-resistance- reversal agent, phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816.
67. Turner RT, Wakley GK, Hannon KS, Bell NH (1987). Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 2: 449-456.
68. Turner RT, Wakley GK, Hannon KS, Bell NH (1988). Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122: 1146-1150.
69. Vidal O, Kindblom LG, Ohlsson C (1999). Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res 14: 923-929.
70. Vidal ON, Sjogren K, Eriksson BI, Ljunggren O, Ohlsson C (1998). Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 248: 696-700.
71. Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH et al. (2003). Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 88: 4206-4213.
72. Ward RL, Morgan G, Dalley D, Kelley PJ (1993). Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22: 87-94.
73. Yang NN, Venugopalan M, Hardikar S, Glasebrook A (1996). Identification of anti estrogen response element activated by metabolities of estradiol and raloxifene. Science 273: 1222-1225.
74. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANC/RANKL. Proc Natl Acad Sci USA 95: 3597-3602.
75. Yoneda K, Tanji Y, Ikeda N, Miyoshi Y, Taguchi T, Tamaki Y et al. (2002). Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett 186: 223-230.